Vidhya Karivedu, MD
Hematology & Oncology · Durham, NCNPI 1114369212
Payments from drug & device makers
What this record shows
That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
Across 68 payments — averaging $4207.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$217K
- Regeneron$69K
How this compares
$0 in reported general payments places this provider in the 0th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 12 | $223 |
| Ondansetron OdtOndansetron | 18 | $125 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Durham
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Matthew McKinneyDurham$277K
- Taewoong ChoiDurham$207K
- Ivy AltomareDurham$164K
- Jeffrey CrawfordDurham$125K
- Carlos de CastroDurham$124K
- Joseph MooreDurham$97K
- Ammon FagerDurham$56K
- Jameel MuzaffarDurham$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.